Jiangsu Hengrui's third FDA nod to bolster global strategy efforts
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang and Shanghai, won FDA approval for its third cancer drug, oxaliplatin, an alkylating agent used to treat colorectal cancer, as the firm's pioneering efforts as a Chinese pharma to pass the hurdles of developed markets begin to pay off.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST